Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study

Geier, Andreas; Eichinger, Mareile L.; Stirnimann, Guido; Semela, David; Tay, Fabian; Seifert, Burkhardt; Tschopp, Oliver; Bantel, Heike; Jahn, Daniel; Maggio, Ewerton Marques; Saleh, Lanja; Bischoff‐Ferrari, Heike A.; Müllhaupt, Beat; Dufour, Jean–François

doi:10.1080/00365521.2018.1501091

Cited by 48 publications

(39 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reason behind this increase in the placebo group is unclear, and may involve a worsening metabolic profile due to the PCOS progression. Whereas there are no comparative data from vitamin D supplementation studies on liver markers in PCOS, the positive changes in markers of liver fibrosis in the present study are in accordance with relevant animal studies demonstrating beneficial effects of vitamin D on liver histology [35,36], but also human studies in patients with NAFLD [23,24,25,37]. For example, Papapostoli et al demonstrated favorable alterations in transient elastography (controlled attenuation parameter) after a 6-month vitamin D treatment (20,000 IU per week) [23].…”

Section: Discussionsupporting

confidence: 89%

“…Emerging evidence has associated NAFLD with vitamin D deficiency, and in epidemiological studies, both conditions share multiple cardiovascular risk factors [21,22]. Some vitamin D supplementation trials have shown positive effects on hepatic steatosis, liver-related biochemical markers, or both in patients with NAFLD [23,24,25]; however, its effects in women with PCOS have not been previously explored.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome

et al. 2019

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemistry in patients with NAFLD; however, its effects on PCOS are unknown. This randomized, double-blind, placebo-controlled study explored the effect of vitamin D supplementation on cardiovascular risk factors (high-sensitivity C-reactive protein (hs-CRP), weight, body mass index (BMI), lipid profile, glucose levels, insulin levels, the homeostatic model assessment-insulin resistance (HOMA-IR), hormones (free androgen index (FAI), testosterone, sex hormone binding globulin (SHBG), and liver markers (alanine aminotransferase (ALT), hyaluronic acid (HA), N-terminal pro-peptide of type III procollagen (PIIINP), tissue inhibitor of metallo-proteinases-1 (TIMP-1), and the enhanced liver fibrosis (ELF) score). Forty women with PCOS were recruited and randomized to vitamin D (3200 IU) or placebo daily for 3 months. All outcomes were measured at baseline and 3 months follow-up (FU). Greater increases in vitamin D levels were shown in the supplementation group (vitamin D, baseline: 25.6 ± 11.4 nmol/L, FU: 90.4 ± 19.5 nmol/L vs. placebo, baseline: 30.9 ± 11.1 nmol/L, FU: 47.6 ± 20.5 nmol/L, p < 0.001). Between groups comparisons (% baseline change) revealed significant differences in ALT (p = 0.042) and a weak effect indicating a greater reduction in the HOMA-IR in the vitamin D group (p = 0.051). No further between group differences were seen in other cardiovascular risk factor, liver markers, or hormones. This study supports beneficial effects of vitamin D supplementation on liver markers and modest improvements in insulin sensitivity in vitamin D deficient women with PCOS.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Although observational studies have implicated low vitamin D levels in the development of liver injury, fibrosis and incident NAFLD, 39,40 small clinical trials have not demonstrated any impact on liver histology. 41,42 In contrast, vitamin E, which has potent antioxidant properties, has been shown to lead to NASH resolution in 36-58% of adults and children, respectively, though not fibrosis improvement. 43,44 EASL and AASLD guidelines recommend considering vitamin E (800 IU/day) for the treatment of non-diabetic non-cirrhotic patients with NASH, although, a recent trial also demonstrated efficacy in patients with T2DM.…”

Section: Impact Of Different Diets On Nafldmentioning

confidence: 99%

Lifestyle modification in NAFLD/NASH: Facts and figures

2019

View full text Add to dashboard Cite

The development of non-alcoholic fatty liver disease is closely linked to lifestyle factors, namely excessive caloric intake coupled with reduced physical activity and exercise. This review aims to examine the evidence behind lifestyle change as a tool to improve hepatic steatosis and liver histology in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Furthermore, potential barriers to adopting lifestyle changes and strategies to overcome these barriers in the clinical setting are discussed.

show abstract

“…Vitamin D supplementation is, hence, an attractive treatment for NAFLD and its progression towards NASH. In a phase 2 clinical trial, 2100 IU of vitamin D for 48 weeks improved serum ALT levels and histology-proven NASH in hypovitaminosis-D patients with NASH [ 87 ]. The frequent manifestation of vitamin D deficiency in NAFLD patient groups necessitates prospective longitudinal studies to determine optimal dosing strategies [ 88 ].…”

Section: Treatmentsmentioning

confidence: 99%

Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease

Smeuninx

Boslem

Febbraio

2020

Cancers

View full text Add to dashboard Cite

Obesity is recognised as a risk factor for many types of cancers, in particular hepatocellular carcinoma (HCC). A critical factor in the development of HCC from non-alcoholic fatty liver disease (NAFLD) is the presence of non-alcoholic steatohepatitis (NASH). Therapies aimed at NASH to reduce the risk of HCC are sparse and largely unsuccessful. Lifestyle modifications such as diet and regular exercise have poor adherence. Moreover, current pharmacological treatments such as pioglitazone and vitamin E have limited effects on fibrosis, a key risk factor in HCC progression. As NAFLD is becoming more prevalent in developed countries due to rising rates of obesity, a need for directed treatment is imperative. Numerous novel therapies including PPAR agonists, anti-fibrotic therapies and agents targeting inflammation, oxidative stress and the gut-liver axis are currently in development, with the aim of targeting key processes in the progression of NASH and HCC. Here, we critically evaluate literature on the aetiology of NAFLD-related HCC, and explore the potential treatment options for NASH and HCC.

show abstract

Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study

Cited by 48 publications

References 19 publications

A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome

A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome

Lifestyle modification in NAFLD/NASH: Facts and figures

Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About